Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)

BACKGROUND: Dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to significantly improve overall survival in the patients of EGFR mutation-positive inoperable or postoperative recurrent non-small cell lung cancer (NSCLC). However, dermatol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Iwasaku, Masahiro, Uchino, Junji, Yamada, Tadaaki, Chihara, Yusuke, Shimamoto, Takayuki, Tamiya, Nobuyo, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749124/
https://ncbi.nlm.nih.gov/pubmed/31555524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.08.03
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados